In line with previous works38, our data indicate that AML CD34+(CD38low/-) cells have enhanced glycolytic activity and altered glucose metabolism that might preferentially promote a resistant phenotype to chemotherapeutic drugs. Here, CD34 is linked to acute myeloid leukemia.